ThermoPharma Baltic - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 6,000 | 16,870 | 37,700 | 67,000 | 25,994 | 30,000 | 31,266 | 1,856 |
| Profit before tax | -9,460 | 4,498 | 10,477 | 66,849 | 3,061 | -95,333 | 223 | -174,023 |
| Net profit | -9,460 | 4,498 | 10,477 | 66,849 | 3,061 | -95,333 | 223 | -174,023 |
| Equity | 12,882 | 17,380 | 27,857 | 94,706 | 97,768 | 2,435 | 2,657 | 30,661 |
| Liabilities | 295 | 103,331 | 144,911 | 131,586 | 172,195 | 93,126 | 101,238 | 2,924 |
| Non-current assets | 646 | 349 | 5,343 | 44,197 | 34,432 | 24,320 | 24,320 | 11,758 |
| Current assets | 12,459 | 120,052 | 167,298 | 181,762 | 235,239 | 71,099 | 79,423 | 21,492 |
| Total assets | 13,105 | 120,401 | 172,641 | 225,959 | 269,671 | 95,419 | 103,743 | 33,250 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 45,870 | 1,632 | 8,649 |
| Social insurance contributions | - | - | - | - | - | 48,076 | - | 11,046 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -76.1% | +181.2% | +123.5% | +77.7% | -61.2% | +15.4% | +4.2% | -94.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -72.2% | 3.7% | 6.1% | 29.6% | 1.1% | -99.9% | 0.2% | -523.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -73.4% | 25.9% | 37.6% | 70.6% | 3.1% | -3915.1% | 8.4% | -567.6% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -157.7% | 26.7% | 27.8% | 99.8% | 11.8% | -317.8% | 0.7% | -9376.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -157.7% | 26.7% | 27.8% | 99.8% | 11.8% | -317.8% | 0.7% | -9376.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.0 | 5.9 | 5.2 | 1.4 | 1.8 | 38.2 | 38.1 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 465 | 1,368 | 2,144 | 3,255 | 1,743 | 4,932 | 31,266 | 309 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
ThermoPharma Baltic - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2022-06-16 | 2022-07-10 | 0.05 |
| 2022-05-17 | 2022-06-02 | 0.05 |
| 2022-04-19 | 2022-05-04 | 0.05 |
| 2022-03-16 | 2022-04-06 | 0.05 |
| 2022-02-17 | 2022-03-03 | 0.05 |
| 2022-01-31 | 2022-02-08 | 1.22 |
| 2022-01-26 | 2022-01-30 | 1.17 |
| 2021-11-16 | 2021-11-16 | 87.94 |
ThermoPharma Baltic - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
ThermoPharma Baltic, UAB (code 303324868) is a Private Limited Liability Company engaged in research and experimental development on other natural sciences and engineering. In the latest financial year, 2025, revenue fell to €1.9K from €31.3K in 2024 and €30.0K in 2023, showing a sharp contraction in activity. The company recorded a net loss of €174.0K in 2025, after a small profit of €223 in 2024 and a loss of €95.3K in 2023. Because turnover was very low in 2025, profitability indicators were heavily distorted, but the result still reflects substantial losses relative to sales. Total assets declined to €33.2K from €103.7K a year earlier. Equity stood at €30.7K and liabilities at €2.9K, which corresponds to an equity ratio of 92.2% and debt-to-equity of 0.10. Asset turnover was 0.06x. Revenue per employee was €309 and profit per employee was -€29.0K, indicating very limited operating scale in 2025.